EPGN.Y Stock Overview
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Epigenomics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.07 |
| 52 Week High | €9.56 |
| 52 Week Low | €8.02 |
| Beta | 1.15 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -96.25% |
| 5 Year Change | -98.91% |
| Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| EPGN.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -3.1% |
| 1Y | n/a | -1.8% | 20.9% |
Return vs Industry: Insufficient data to determine how EPGN.Y performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how EPGN.Y performed against the US Market.
Price Volatility
| EPGN.Y volatility | |
|---|---|
| EPGN.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EPGN.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EPGN.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 36 | Greg Hamilton | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
| EPGN.Y fundamental statistics | |
|---|---|
| Market cap | US$2.77m |
| Earnings (TTM) | -US$7.87m |
| Revenue (TTM) | US$615.03k |
4.5x
P/S Ratio-0.4x
P/E RatioIs EPGN.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPGN.Y income statement (TTM) | |
|---|---|
| Revenue | €567.00k |
| Cost of Revenue | €138.00k |
| Gross Profit | €429.00k |
| Other Expenses | €7.68m |
| Earnings | -€7.25m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Apr 21, 2023
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 75.66% |
| Net Profit Margin | -1,279.54% |
| Debt/Equity Ratio | 0% |
How did EPGN.Y perform over the long term?
See historical performance and comparison